Education
About Us
Working with TipRanks
Follow Us
Amgen (HK:4332)
:4332
4332 Stock Chart & Stats
HK$0.18
-HK$665.82(-99.97%)
At close: 4:00 PM EST
HK$0.18
-HK$665.82(-99.97%)
Day’s Range― - ―
52-Week RangeHK$0.19 - HK$1,761.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$1.34T
Enterprise ValueHK$198.09B
Total Cash (Recent Filing)$9.45B
Total Debt (Recent Filing)$54.59B
Price to Earnings (P/E)<0.1
Beta0.00
Next Earnings
Feb 03, 2026EPS Estimate
37.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)43.85
Shares Outstanding538,361,900
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.88
Price to Book (P/B)23.99
Price to Sales (P/S)4.22
P/FCF Ratio13.57
Enterprise Value/Market Cap0.15
Enterprise Value/Revenue5.51
Enterprise Value/Gross Profit8.33
Enterprise Value/Ebitda11.98
Forecast
1Y Price Target
$2,503.63Price Target Upside1390807.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
EarningsAmgen's third-quarter revenues came in at $9.6 billion, beating the estimate and consensus of $9.0 billion.
GuidanceAmgen raised 2025 revenue and EPS guidance, indicating confidence in future performance.
Product GrowthRepatha revenue increased 40% YoY, reflecting strong efforts by Amgen.
Bears Say
Horizon Portfolio PerformanceThe Horizon portfolio is still underperforming some expectations for investors.
Regulatory And Market RisksLong-term Repatha risks remain, with anticipated Medicare Part D IRA price controls and potential biosimilar competition after loss of exclusivity.
ValuationAMGN is considered overvalued as it trades at a P/E multiple slightly above average.
Amgen News
4332 FAQ
What was Amgen’s price range in the past 12 months?
Amgen lowest stock price was HK$0.18 and its highest was HK$1761.00 in the past 12 months.
What is Amgen’s market cap?
Amgen’s market cap is $1.34T.
When is Amgen’s upcoming earnings report date?
Amgen’s upcoming earnings report date is Feb 03, 2026 which is in 86 days.
How were Amgen’s earnings last quarter?
Amgen released its earnings results on Nov 04, 2025. The company reported HK$43.851 earnings per share for the quarter, beating the consensus estimate of HK$39.023 by HK$4.828.
Is Amgen overvalued?
According to Wall Street analysts Amgen’s price is currently Undervalued.
Does Amgen pay dividends?
Amgen does not currently pay dividends.
What is Amgen’s EPS estimate?
Amgen’s EPS estimate is 37.61.
How many shares outstanding does Amgen have?
Amgen has 538,361,900 shares outstanding.
What happened to Amgen’s price movement after its last earnings report?
Amgen reported an EPS of HK$43.851 in its last earnings report, beating expectations of HK$39.023. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Amgen?
Currently, no hedge funds are holding shares in HK:4332
Amgen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2,503.63 (1390807.42% Upside)
$2,503.63 (1390807.42% Upside)
Blogger Sentiment
Bullish
HK:4332 Sentiment 82%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
1.35%
12-Months-Change
Fundamentals
Return on Equity
81.71%
Trailing 12-Months
Asset Growth
-0.82%
Trailing 12-Months
Company Description
Amgen
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
4332 Company Deck
4332 Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call showcased strong financial performance with a 12% revenue increase and significant volume growth driven by key products. There were notable advances in cardiovascular studies and the biosimilar portfolio, alongside new initiatives like AmgenNow to improve patient access. However, the call also highlighted challenges such as increased competition in certain segments, generic impacts on rare disease products, and some delays in study readouts. Overall, the positives in growth and strategic initiatives outweighed the negatives.View all HK:4332 earnings summaries4332 Revenue Breakdown
13.09% Prolia
9.92% Enbrel
6.66% XGEVA
6.65% Repatha
63.69% Other
4332 Stock 12 Month Forecast
Average Price Target
HK$2,503.63
―
Technical Analysis
Options Prices
Currently, No data available
---